CorMedix has seen a sharp reset in its share price this year, and the scale of that drop puts a spotlight on whether the current valuation lines up with what its earnings can support. With investors also weighing a sizeable acquisition, the key issue is how much of CorMedix's future profit picture is already baked into today's US$4.66 share price.
The issue now is whether CorMedix's current earnings and the price investors are paying for them look aligned.
To see how CorMedix compares with other opportunities focused on earnings power and price reset stories, evaluate it alongside companies in the 37 high quality undervalued stocks
The P/E ratio fits CorMedix because earnings are front and center in how investors are framing the story. On this measure, CorMedix trades on roughly 5.8x earnings, which is less than half the Pharmaceuticals industry average of about 17.1x and also below the peer group at around 12.8x. That puts a lot of weight on whether current profits are sustainable in light of the business model and upcoming integration work.
Because the fair P/E implied by the valuation model sits higher than the current figure, the shares screen as undervalued on this earnings multiple alone. The planned Heron Therapeutics asset acquisition is expected to support earnings and free cash flow, yet despite that backdrop the P/E still reflects a sizeable discount to sector and peer benchmarks. Explore the numbers behind CorMedix's P/E valuation.
Simply Wall St Narratives picks up where the CorMedix valuation puzzle leaves off. It spells out which assumptions about future growth, margins and earnings would need to hold for the current share price to look too low or too high. Each scenario on the Community page links a fair value estimate to a particular combination of potential catalysts and risks, so you can track over time which version of CorMedix's story appears to be unfolding.
One of the top community narratives on CorMedix: 64% undervalued
According to CourtStreetCapital, an investor in the Simply Wall St Community, CorMedix looks mispriced once you factor in its protected DefenCath franchise and the upcoming REZZAYO decision.
"DefenCath has a durable position. It is the only FDA-approved antimicrobial catheter lock solution in the U.S., with exclusivity into the 2030s and patents to 2042…"
Discover why this Narrative puts CorMedix at 64% undervalued.
Before you close the book on CorMedix based on P/E and deal headlines, it helps to see where analyst expectations place this business a few years from now compared with today. Explore where analysts expect CorMedix to be in a few years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com